SynthesisFrontiers in pharmacology2025
Evaluating dexmedetomidine in mitigating emergence agitation and perioperative complications in pediatric tonsillectomy and/or adenoidectomy: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative complications and emergence agitation (EA) are common after pediatric tonsillectomy and/or adenoidectomy (T&A), and may be influenced by the use of preoperative sedatives. The effectiveness of dexmedetomidine (Dex) in minimizing these risks is still debated. Methods: We searched EMBASE, PubMed, and the Cochrane Library for randomized controlled trials (RCTs) assessing the safety and effectiveness of Dex in pediatric T&A, with comparisons made against placebo and/or alternative comparators. The search included studies published before March 2025. Retrieved data included the incidence of EA, the percentage (%) of cases requiring rescue analgesics, and perioperative complications, such as hypotension and bradycardia, and perioperative respiratory adverse events (PRAEs). The meta-analysis was performed using RevMan 5.3. Results: Thirty-six RCTs including 3,773 children were included. Compared with placebo, benzodiazepines, and opioids, Dex significantly reduced the occurrence of EA [OR = 0.23, 95% CI (0.16, 0.32), I Conclusion: Dex may mitigate EA and perioperative complications while enhancing recovery quality following T&A in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.